How does chronic high blood sugar in Type 2 diabetes lead to long-term damage in major organs, and what are the mechanisms underlying these complications
DOI:
https://doi.org/10.58445/rars.2396Keywords:
Type 2 Diabetes Mellitus (T2D), Chronic Hyperglycemia, Oxidative Stress, Reactive Oxygen Species (ROS), Advanced Glycation End-products (AGEs), Continuous Glucose Monitoring (CGM), HbA1c MonitoringAbstract
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by sustained hyperglycemia, which brings on a host of pathogenic events leading to the development of long term organ damage. This paper seeks to explain how chronic elevations in blood sugar levels result in long-term damage to major organs through discussions on associated pathophysiological mechanisms and processes. The prevalence of T2D continues to rise globally; hence, it is a major public health and socioeconomic challenge. In a series of mechanisms, chronic hyperglycemia enhances cellular and metabolic injury by inducing oxidative stress, mitochondrial dysfunction, inflammation, endothelial damage, and production of
AGEs. These interrelated pathways result in the devastating complications of diabetic nephropathy, retinopathy, neuropathy, and cardiovascular disease, each contributing to increased morbidity and mortality. Oxidative stress in T2D results in the overproduction of ROS; these, in turn, damage cellular constituents and promote chronic inflammation. Also, mitochondrial dysfunction further increases ROS production, decelerates the ATP-producing machinery, and increases apoptosis.
Inflammatory responses resulting from persistent hyperglycemia are manifested by cytokine release that promotes tissue injury. Impaired endothelial function gives rise to vascular integrity disruption with restricted blood flow, thereby leading to some complications of nephropathy and retinopathy. The non-enzymatic reactions between sugar and proteins or lipids form AGEs, contributing to tissue rigidity and vascular complications with regard to the binding of receptors,
enhancing oxidative stress and inflammation. Diabetic nephropathy is one of the major causes of ESRD. This is characterized by reduced glomerular filtration rate and progressive glomerular injury mediated by AGEs and endothelial injury. Diabetic retinopathy is the damage to the blood vessels of the retina, leading to loss of vision due to abnormal and fragile proliferation of the vessels. Neuropathy involves degeneration of the nerves, thus impairing sensory and autonomic functions due to chronic oxidative stress and inflammation.
References
- American Diabetes Association. (2022). Diabetes care.
- Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023). Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy, 168(168), 115734.
- Brownlee, M. (2018). The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54(6), 1615-1625.
- Buse, J. B., et al. (2020). Management of hyperglycemia in type 2 diabetes. Diabetes Care, 43(11), 2755–2759.
- Cade, W. T. (2008). Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical Therapy, 88(11), 1322–1335.
- Cersosimo, E., et al. (2018). Pathophysiology of T2D. Endocrine Reviews, 39(5), 734–764.
- Cho, N. H., et al. (2018). IDF Diabetes Atlas. Diabetes Research and Clinical Practice, 138, 271–281.
- Continuous glucose monitoring. (2024, April 18). National Institute of Diabetes and Digestive and Kidney Diseases.
- De Mattos Matheus, A. S., Tannus, L. R. M., Cobas, R. A., Palma, C. C. S., Negrato, C. A., & De Brito Gomes, M. (2013). Impact of diabetes on cardiovascular disease: An update. International Journal of Hypertension, 2013, 1–15.
- DeFronzo, R. A., et al. (2019). Pathogenesis of type 2 diabetes mellitus. Diabetes Spectrum, 31(4), 237–248.
- Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of diabetes and diabetes-related complications. Physical Therapy, 88(11), 1254–1264.
- Diabetic neuropathy - Symptoms & causes - Mayo Clinic. (2022, April 29). Mayo Clinic.
- Diabetic retinopathy - Symptoms & causes - Mayo Clinic. (2023, February 21). Mayo Clinic.
- Donath, M. Y., & Shoelson, S. E. (2021). Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 11(2), 98–107.
- Esser, N., et al. (2020). Inflammation as a link between obesity, metabolic syndrome, and type 2 diabetes. Diabetes Research and Clinical Practice, 105(2), 141–150.
- Evans, J. L., et al. (2019). Oxidative stress and stress-activated signaling pathways. Diabetes Technology & Therapeutics, 14(9), 773-789.
- Forbes, J. M., & Cooper, M. E. (2021). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137–188.
- Gheith, O., Farouk, N., Nampoory, N., Halim, M. A., & Al-Otaibi, T. (2015, October 9). Diabetic kidney disease: Worldwide difference of prevalence and risk factors.
- Giugliano, D., et al. (2018). Oxidative stress and diabetic complications. Journal of Diabetes & Metabolism, 9(8), 773-789.
- Goldin, A., et al. (2019). Advanced glycation end-products in diabetes and other diseases. New England Journal of Medicine, 355(4), 394–406.
- Gregg, E. W., et al. (2019). Trends in diabetes complications. Diabetes Care, 41(3), 280-286.
- Hotamisligil, G. S. (2019). Inflammation and metabolic disorders. Nature, 444(7121), 860-867.
- IDF (International Diabetes Federation). (2021). IDF Diabetes Atlas. Diabetes Research and Clinical Practice, 138, 271–281.
- IDF Diabetes Atlas. (n.d.). Copyright © IDF Diabetes Atlas 2024.
- Khan, M. A., et al. (2020). Socioeconomic impact of diabetes. The Lancet Diabetes & Endocrinology, 7(9), 673-679.
- Lowell, B. B., & Shulman, G. I. (2019). Mitochondrial dysfunction and type 2 diabetes. Science, 307(5708), 384–387.
- Maechler, P., & Wollheim, C. B. (2020). Mitochondrial signaling in diabetes. Endocrine Reviews, 23(5), 252-271.
- Nicholls, D. G. (2018). Mitochondria and calcium signaling. Cell Calcium, 44(3), 259-263.
- Odegaard, J. I., & Chawla, A. (2020). Mechanisms of inflammation in T2D. Diabetes, 61(6), 1376–1386.
- Pankow, J. S., et al. (2018). Cytokine levels and T2D. Diabetologia, 45(4), 485-491.
- Petersen, K. F., & Shulman, G. I. (2018). Pathogenesis of insulin resistance. Annual Review of Medicine, 57, 233–243.
- Pickup, J. C. (2019). Inflammation and T2D. Diabetes Technology & Therapeutics, 10(9), 497–506.
- Saeedi, P., et al. (2019). Global and regional diabetes prevalence. Diabetes Research and Clinical Practice, 157, 107843.
- Taylor, R. (2020). Insulin resistance and T2D progression. Diabetologia, 50(1), 198-208.
- Type 2 diabetes. (2024, October 11). Cleveland Clinic.
- Vlassara, H., & Uribarri, J. (2013). Advanced glycation end products (AGE) and diabetes: Cause, effect, or both? Current Diabetes Reports, 14(1).
- Vlassara, H., et al. (2019). Advanced glycation and diabetes. Diabetes & Metabolism, 31(4), 139-144.
- Wandile, P. M. (2023). Diabetic nephropathy and management. SCIRP.
- Wang, C., et al. (2020). Role of oxidative stress in T2D. Antioxidants & Redox Signaling, 26(4), 1405-1420.
- Yamagishi, S., & Matsui, T. (2020). Role of advanced glycation end-products in diabetes. Clinical Science, 116(8), 57–67.
- Zheng, Y., et al. (2018). Global diabetes statistics. Diabetes Spectrum, 30(3), 204–212.
Downloads
Posted
Categories
License
Copyright (c) 2025 Renad Shady

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.